Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636729 | 0.85 | P2RX7 (0.57) | P2RX7ADRB1ACACBHCRTR1HCRTR2 | |
| SCHEMBL1637683 | 0.80 | P2RX7 (0.61) | P2RX7HCRTR1HCRTR2 | |
| SCHEMBL1637138 | 0.79 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL1636535 | 0.79 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL1636656 | 0.77 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL1637979 | 0.76 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL1636163 | 0.76 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL14041470 | 0.76 | P2RX7 (0.68) | P2RX7 | |
| SCHEMBL14041386 | 0.75 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL1636766 | 0.75 | P2RX7 (0.61) | P2RX7ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932282-B2 | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2011-04-26 | — | — | US | disclosed |
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| CN-101679291-A | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2142512-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119825-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX5 | P2RX7 2/4885PKM 1070/4885SLC6A7 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.